Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab versus pemetrexed with cisplatin or carboplatin as first-line therapy for unresectable pleural mesothelioma
jRCT2080223370Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pleural mesothelioma comparing Nivolumab + ipilimumab with Pemetrexed + cisplatin or carboplatin (2 arms). Started Nov 2016; status: completed.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on jRCT2080223370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223370.